ST. HELIER, Jersey–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AACR19?src=hash" target="_blank"gt;#AACR19lt;/agt;–The recipients of the AACR-Novocure Tumor Treating Fields research
grants were announced on April 2 at the American Association for Cancer
Research (AACR) Annual Meeting 2019 in Atlanta. The grants represent a
joint effort between Novocure (NASDAQ: NVCR) and the AACR to promote and
support innovative research on Tumor Treating Fields.
“This truly remarkable partnership will provide the critical resources
needed to accelerate progress in this exciting and burgeoning field,”
said Mitch Stoller, Chief Philanthropic Officer and Vice President of
Development. “We are incredibly grateful to Novocure for their vision
and commitment to advancing innovative cancer research.”
“Congratulations to the recipients of the Tumor Treating Fields research
grants,” said Asaf Danziger, Novocure’s Chief Executive Officer. “We
value our partnership with the AACR on this program and look forward to
learning the outcomes of the impressive research planned by our grant
recipients.”
2019 AACR-Novocure Tumor Treating Fields Research Grants
-
Matthew R. Sarkisian, PhD; University of Florida; Enhancing
TTFields therapy for glioma by dual inhibition of HDAC6 and SIRT2 -
Michael D. Story, PhD; University of Texas Southwestern Medical Center
at Dallas; Exploiting the conditional vulnerabilities caused by
TTFields exposure -
Emil Lou, MD, PhD; Regents of the University of Minnesota – Twin
Cities; ECM-mimicking platform for testing TTFields and
intercellular communication
2019 AACR-Novocure Career Development Award for Tumor Treating Fields
Research
-
Alexander Rubinsteyn, PhD; Icahn School of Medicine at Mount Sinai; Impact
of Tumor Treating Fields on neoantigen burden and T cell function
2019 AACR-Novocure Tumor Treating Fields Research Fellowships
-
Francesca Anna Carrieri, PhD; The Ohio State University; Centrosome
clustering inhibition to enhance Tumor Treating Fields -
Preshita Desai, B Pharm, PhD; Western University of Health Sciences; Tumor
Treating Fields triggered targeting of nanoparticles in cancer
About Novocure
Novocure is a global oncology company working to extend survival in some
of the most aggressive forms of cancer by developing and commercializing
its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is
a cancer therapy that uses electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s commercialized
product is approved for the treatment of adult patients with
glioblastoma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in mesothelioma, brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver
cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
About the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is
the world’s first and largest professional organization dedicated to
advancing cancer research and its mission to prevent and cure cancer.
AACR membership includes more than 42,000 laboratory, translational, and
clinical researchers; population scientists; other health care
professionals; and patient advocates residing in 120 countries. The AACR
marshals the full spectrum of expertise of the cancer community to
accelerate progress in the prevention, biology, diagnosis, and treatment
of cancer by annually convening more than 30 conferences and educational
workshops, the largest of which is the AACR Annual Meeting with more
than 22,500 attendees. In addition, the AACR publishes eight
prestigious, peer-reviewed scientific journals and a magazine for cancer
survivors, patients, and their caregivers. The AACR funds meritorious
research directly as well as in cooperation with numerous cancer
organizations. As the Scientific Partner of Stand Up To Cancer, the AACR
provides expert peer review, grants administration, and scientific
oversight of team science and individual investigator grants in cancer
research that have the potential for near-term patient benefit. The AACR
actively communicates with legislators and other policymakers about the
value of cancer research and related biomedical science in saving lives
from cancer. For more information about the AACR, visit www.AACR.org.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory submission and approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify some
of these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions as well as more
specific risks and uncertainties facing Novocure such as those set forth
in its Annual Report on Form 10-K filed on February 28, 2019, with the
U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend to
update publicly any forward-looking statement, except as required by
law. Any forward-looking statements herein speak only as of the date
hereof. The Private Securities Litigation Reform Act of 1995 permits
this discussion.
Contacts
Media and Investors:
Ashley Cordova
acordova@novocure.com
212-767-7558